2025
Multicenter performance comparison of the hepatitis C antibody serology assay on the new Atellica integrated chemistry and immunoassay analyzer
El-Khoury J, Bonito A, Fonstad R, Anostario M, Quintanilla M, Birmingham N, Mohammad A. Multicenter performance comparison of the hepatitis C antibody serology assay on the new Atellica integrated chemistry and immunoassay analyzer. Journal Of Clinical Virology Plus 2025, 5: 100215. DOI: 10.1016/j.jcvp.2025.100215.Peer-Reviewed Original ResearchHepatitis C virusHCV seroconversion panelsSeroconversion panelsRisk of transmitting HCVExposure to hepatitis C virusIMS analyzerHepatitis C virus serologic testsSerological testsAnti-HCV serological testAnti-HCV antibodiesSerological assaysCenters for Disease ControlIntegrative chemistryC virusSerum specimensIncreased riskNegative individualsAtellicaClinical performanceImmunoassay analyzerPositive individualsIdentification of individualsMethod comparison studyDisease controlPositive agreementModern-Day Hypofractionated Postmastectomy Radiation
Rybkin A, Bodofsky S, Knowlton C. Modern-Day Hypofractionated Postmastectomy Radiation. Current Breast Cancer Reports 2025, 17: 7. DOI: 10.1007/s12609-025-00570-9.Peer-Reviewed Original ResearchPostmastectomy radiationBreast cancerPost-mastectomy settingRegional nodal irradiationRadiobiological dataQuality of life metricsNodal irradiationBreast conservationEradicate tumorsComplication rateBrachial plexopathyPostmastectomy patientsToxicity profileHypofractionationFractionation schemaTherapeutic windowReviewThis reviewTissue effectsTrial dataBreastPostmastectomyStandard optionDisease controlPatientsCancer
2024
Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies
Issa N, Chovatiya R, Talia J, Torres T, Eyerich K, Calimlim B, Yang Y, Pechonkina A, Moreira A, Grada A, Bunick C. Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. SKIN The Journal Of Cutaneous Medicine 2024, 8: s449. DOI: 10.25251/skin.8.supp.449.Peer-Reviewed Original ResearchAtopic dermatitisModerate-to-severe atopic dermatitisLong-term disease controlClinically meaningful responseProlonged systemic therapyProportion of patientsUpadacitinib treatmentOptimal treatment targetsSystemic therapyOptimal treatmentMeaningful responseJAK inhibitorsInterim analysisPatientsUpadacitinibLong-term maintenanceTreatment targetItchingOptimal outcomesWeeksDermatitisDisease controlOutcomesSkinPhase 3BEING ATTACK-FREE WITH GARADACIMAB IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Hsu F, Lumry W, Aygoren-Pursun E, Braverman J, Lawo J, Pollen M, Nenci C, Craig T. BEING ATTACK-FREE WITH GARADACIMAB IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY ANGIOEDEMA. Annals Of Allergy Asthma & Immunology 2024, 133: s33-s34. DOI: 10.1016/j.anai.2024.08.129.Peer-Reviewed Original ResearchOpen-label extensionAttack-free patientsHereditary angioedemaHRQoL improvementAttack-freeImpaired health-related quality of lifeHealth-related quality of lifeAE-QoLClinically meaningful HRQoL improvementAssociated with HRQoL improvementsExposure cohortPhase 3 studySustained HRQoL improvementQuality of lifePost Hoc AnalysisHRQOL outcomesScore reductionHRQoLPatientsHoc AnalysisCohortTreatment goalsImpairment scoresAngioedemaDisease controlTumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 35: 73-83. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular Carcinoma ImmunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting Overall SurvivalCox regression modelsSurvival benefitStratify patientsMRI pre-P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study
Wang Z, Yang M, Chao J, Martins B, Chuang C, Shumel B, Sierka D, Carboni M, Strober B. P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study. British Journal Of Dermatology 2024, 191: i63-i64. DOI: 10.1093/bjd/ljae090.128.Peer-Reviewed Original ResearchAtopic dermatitisEpisodes of itchingTreatment satisfactionMonth 1Disease controlClinical practiceProportion of patientsPatient survey studyPercentage of patientsSustained improvementFollow-up resultsPrescribed dupilumabGeneralized Estimating EquationsQuality of lifePatient support programmeSingle-armDupilumabSkin symptomsBaseline surveyPatientsSupport programmesPatient satisfactionPractice guidelinesStatistical significanceMonths
2023
Pneumococcal Infections in Children with Sickle Cell Disease Before and After Pneumococcal Conjugate Vaccines
Adamkiewicz T, Yee M, Thomas S, Tunali A, Lai K, Omole F, Lane P, Yildirim I. Pneumococcal Infections in Children with Sickle Cell Disease Before and After Pneumococcal Conjugate Vaccines. Blood Advances 2023, 7: 6751-6761. PMID: 37698500, PMCID: PMC10660014, DOI: 10.1182/bloodadvances.2022009643.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSickle cell diseaseCell diseasePCV13-serotype invasive pneumococcal diseaseSerotype invasive pneumococcal diseaseNon-PCV13 serotypesPneumococcal polysaccharide vaccinePneumococcal conjugate vaccineIncidence rate ratiosYears of vaccinationReference populationLife-threatening risksIPD episodesIPD serotypesPneumococcal diseasePneumococcal infectionPolysaccharide vaccineConjugate vaccineHemoglobin SSVaccine licensureEffective vaccinePenicillin resistanceDisease controlVaccineAfrican American childrenTotal and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosisPrevalence and Correlates of Physical Inactivity Among Individuals with HIV During the First COVID-19 Wave: A Cross-sectional Survey
Harsono D, Deng Y, Chung S, Barakat L, Friedland G, Villanueva M, Yager J, Justen M, Edelman E. Prevalence and Correlates of Physical Inactivity Among Individuals with HIV During the First COVID-19 Wave: A Cross-sectional Survey. AIDS And Behavior 2023, 28: 1531-1545. PMID: 37824037, PMCID: PMC11349050, DOI: 10.1007/s10461-023-04170-5.Peer-Reviewed Original ResearchPhysical activity guidelinesPhysical inactivityPhysical activityDetectable HIV viral loadSelf-reported physical activitySample of PWHHIV viral loadPhysical activity levelsUnhealthy alcohol useFirst COVID-19 waveImproved health outcomesCross-sectional surveyHIV clinicCOVID-19 waveActivity guidelinesAdjusted analysisCOVID-19 transmissionViral loadTobacco useCoping strategiesSedentary lifestyleLower oddsPsychological coping strategiesHealth outcomesDisease controlStress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond
Lozar T, Laklouk I, Golfinos A, Gavrielatou N, Xu J, Flynn C, Keske A, Yu M, Bruce J, Wang W, Kuhar C, Bailey H, Harari P, Dinh H, Rimm D, Hu R, Lambert P, Fitzpatrick M. Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond. Cancers 2023, 15: 4905. PMID: 37835599, PMCID: PMC10571921, DOI: 10.3390/cancers15194905.Peer-Reviewed Original ResearchImmune check-point blockadeNeck squamous cell carcinomaCheck-point blockadeSquamous cell carcinomaCK17 expressionDisease controlHNSCC patientsCell carcinomaPredictive biomarkersResponse rateKeratin 17Pembrolizumab-based therapyPembrolizumab-treated patientsPD-L1 expressionProgression-free survivalRNA expressionIndependent retrospective cohortsIndependent validation cohortDecreased response rateLow response rateREMARK criteriaOverall survivalProgressive diseaseRetrospective cohortCXCL10 chemokinesMixed donor chimerism following stem cell transplantation for sickle cell disease
Shah N, Rangarajan H, Ngwube A, Shenoy S. Mixed donor chimerism following stem cell transplantation for sickle cell disease. Current Opinion In Hematology 2023, 30: 187-193. PMID: 37694765, DOI: 10.1097/moh.0000000000000786.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationDonor/recipient chimerismStem cell transplantationSickle cell diseasePost-HCTRecipient chimerismDonor chimerismCell transplantationCell diseaseDisease controlDonor-derived erythropoiesisHCT conditioning regimensMixed donor chimerismSerial chimerism analysesRecent clinical trialsDonor erythropoiesisConditioning regimensHigh morbidityCurative interventionsClinical trialsSuccessful engraftmentSCD manifestationsMyeloid cellsHb S traitChimerism analysisModelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City
Pandey A, Fitzpatrick M, Moghadas S, Vilches T, Ko C, Vasan A, Galvani A. Modelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City. The Lancet Regional Health - Americas 2023, 24: 100555. PMID: 37554154, PMCID: PMC10405058, DOI: 10.1016/j.lana.2023.100555.Peer-Reviewed Original ResearchHealthcare costsVaccine dosesInfluenza vaccine coverageCOVID-19 illnessDirect healthcare costsSevere health outcomesCOVID-19 vaccineCOVID-19 burdenNew York CityBooster vaccineVaccine coverageVaccination ratesBivalent vaccineBase case scenarioHealth outcomesEligible residentsProbable casesDisease controlVaccineCanadian InstituteCOVID-19VaccinationHealth researchCommonwealth FundOutcomes1184-P: No Increased Risk of Gestational Diabetes Mellitus (GDM) Diagnosis after COVID-19 Vaccination
VESCO K, DENOBLE A, LIPKIND H, KHARBANDA E, DESILVA M, DALEY M, GETAHUN D, ZERBO O, NALEWAY A, JACKSON L, WILLIAMS J, BOYCE T, FULLER C, VAZQUEZ BENITEZ G. 1184-P: No Increased Risk of Gestational Diabetes Mellitus (GDM) Diagnosis after COVID-19 Vaccination. Diabetes 2023, 72 DOI: 10.2337/db23-1184-p.Peer-Reviewed Original ResearchCOVID-19 vaccinationCOVID-19 vaccineRisk of GDMCOVID-19 vaccine dosesNon-Hispanic whitesGDM diagnosisVaccine dosesDisease controlGestational diabetes mellitus diagnosisDe novo diabetesRate of GDMDiagnosis of GDMVaccine Safety DatalinkPfizer Inc.Confidence intervalsICD-10 codesNon-Hispanic blacksDiabetes mellitus diagnosisOutcomes Research InstituteNon-Hispanic AsiansHealth care systemNonpregnant adultsUnvaccinated individualsIncreased riskRelative riskTwenty-Year Disparity Trends in United States Stroke Death Rate by Age, Race/Ethnicity, Geography, and Socioeconomic Status
de Havenon A, Zhou L, Johnston K, Dangayach N, Ney J, Yaghi S, Sharma R, Abbasi M, Delic A, Majersik J, Anadani M, Tirschwell D, Sheth K. Twenty-Year Disparity Trends in United States Stroke Death Rate by Age, Race/Ethnicity, Geography, and Socioeconomic Status. Neurology 2023, 101: e464-e474. PMID: 37258298, PMCID: PMC10401675, DOI: 10.1212/wnl.0000000000207446.Peer-Reviewed Original ResearchConceptsStroke death ratesSocial deprivation indexSocial determinantsDeath rateOlder individualsYoung individualsCounty-level social determinantsHigher social deprivation indexDeprivation indexNon-Hispanic white individualsPublic health strategiesHigher substance abuseMedical insurance coverageCounty-level increasesRace/ethnicityStroke deathsStroke mortalityBlack raceDistinct social determinantsHealth strategiesAge groupsDisease controlSubstance abusePercentage changeSocioeconomic statusImplementing a Surveillance-Based Approach to Create a Statewide Viral Clearance Cascade for Hepatitis C Among People With HIV and HCV Coinfection in Connecticut
Wegener M, Brooks R, Speers S, Nichols L, Villanueva M. Implementing a Surveillance-Based Approach to Create a Statewide Viral Clearance Cascade for Hepatitis C Among People With HIV and HCV Coinfection in Connecticut. Public Health Reports 2023, 139: 208-217. PMID: 37232422, PMCID: PMC10851907, DOI: 10.1177/00333549231172173.Peer-Reviewed Original ResearchHIV viral loadHCV coinfectionViral loadSurveillance databaseUndetectable HIV viral loadDetectable HIV viral loadDisease controlHIV/AIDS Reporting SystemHCV elimination strategyRecent HIV testAIDS Reporting SystemElectronic Disease Surveillance SystemOutcomes of peoplePublic health departmentsDisease surveillance systemsSurveillance-based approachHCV cureHCV statusHepatitis CAntiviral medicationsHIV testC virusViral testingHealth departmentsInitial infectionExcess Mortality and Years of Potential Life Lost Among the Black Population in the US, 1999-2020
Caraballo C, Massey D, Ndumele C, Haywood T, Kaleem S, King T, Liu Y, Lu Y, Nunez-Smith M, Taylor H, Watson K, Herrin J, Yancy C, Faust J, Krumholz H. Excess Mortality and Years of Potential Life Lost Among the Black Population in the US, 1999-2020. JAMA 2023, 329: 1662-1670. PMID: 37191702, PMCID: PMC10189563, DOI: 10.1001/jama.2023.7022.Peer-Reviewed Original ResearchConceptsExcess mortality ratesExcess deathsMortality ratePotential lifeWhite populationExcess mortalitySerial cross-sectional studyHighest excess mortality ratesBlack populationCause-specific mortalityCross-sectional studyHigh mortality rateNon-Hispanic whitesYears of lifeUS national dataMiddle-aged adultsCause mortalityHeart diseaseDeath certificatesNon-Hispanic black populationMAIN OUTCOMEAge groupsDisease controlMortalityBlack malesA continent-wide effort and solidarity at curbing COVID-19 pandemic: the Africa task force for novel coronavirus (AFTCOR) infection prevention and control technical working group’s experience
Paintsil E, Alimi Y, Abdulaziz M, Ogbuagu O, Ogunsola F, Kessy S, Horsney E, Lee C, Brundney K, Okwor T, Kabwe P, Waheed A, Vondran A, Bigirimana R, Ilesanmi O, Nsubuga D, Raji T, Mankoula W, Ihekweazu C, Nkengasong J. A continent-wide effort and solidarity at curbing COVID-19 pandemic: the Africa task force for novel coronavirus (AFTCOR) infection prevention and control technical working group’s experience. BMC Public Health 2023, 23: 893. PMID: 37189137, PMCID: PMC10184057, DOI: 10.1186/s12889-023-15706-8.Peer-Reviewed Original ResearchConceptsInfection preventionCDC websiteNovel coronavirus disease (COVID-19) outbreakService delivery pointsCoronavirus disease (COVID-19) outbreakTask ForceIPC trainingResearch subgroupsIPC programIPC measuresHealth personnelDisease controlWorking GroupImplementation researchOutbreaks of diseaseSubgroupsPreventionCOVID-19COVID-19 pandemicTechnical Working GroupAfrica CentrePerson trainingTraining subgroupFocal personsDisease outbreaksPopulation-Level Health Effects of Involuntary Displacement of People Experiencing Unsheltered Homelessness Who Inject Drugs in US Cities
Barocas J, Nall S, Axelrath S, Pladsen C, Boyer A, Kral A, Meehan A, Savinkina A, Peery D, Bien M, Agnew-Brune C, Goldshear J, Chiang J, Linas B, Gonsalves G, Bluthenthal R, Mosites E, Wortley P, Todd J, Melton D, Flynn C, German D, Klevens M, Doherty R, O'Cleirigh C, Jimenez A, Clyde T, Poe J, Vaaler M, Deng J, Al-Tayyib A, Shodell D, Higgins E, Griffin V, Sanger C, Khuwaja S, Lopez Z, Padgett P, Kwa Sey E, Ma Y, Santacruz H, Brantley M, Mathews C, Marr J, Spencer E, Nixon W, Forrest D, Anderson B, Tate A, Abrego M, Robinson W, Barak N, Beckford J, Braunstein S, Rivera A, Carrillo S, Ibrahim A, Wogayehu A, Moraga L, Brady K, Shinefeld J, Nnumolu C, Menza T, Orellana E, Bhattari A, Flynn A, Chambers O, Ramos M, McFarland W, Lin J, Miller D, Miranda De Leon S, Rolon-Colon Y, Martinez M, Jaenicke T, Glick S, Kienzle J, Smith B, Reid T, Opoku J, Kuo I, Adams M, Baugher A, Broz D, Burnett J, Chambers S, Chapin-Bardales J, Denning P, Finlayson T, Handanagic S, Hickey T, Kanny D, Lee K, Lewis R, Morris E, Olansky E, Robbins T, Sionean C, Smith A, Teplinskaya A, Trujillo K, Wejnert C, Whiteman A, Xia M. Population-Level Health Effects of Involuntary Displacement of People Experiencing Unsheltered Homelessness Who Inject Drugs in US Cities. JAMA 2023, 329: 1478-1486. PMID: 37036716, PMCID: PMC10087093, DOI: 10.1001/jama.2023.4800.Peer-Reviewed Original ResearchConceptsNational HIV Behavioral Surveillance SystemInitiation of medicationInjection-related infectionsOpioid use disorderUse disordersHealth effectsInjection drug useLong-term health effectsDrug-related morbidityPopulation attributable fractionBehavioral Surveillance SystemSubstance use disordersMAIN OUTCOMEOverdose deathsRepresentative cohortAdditional deathsOverdose mortalityHealth outcomesDrug useNatural historyDisease controlMortalityDisorder outcomesDrugsHealth implicationsNational trends in alcohol and substance use among adolescents from 2005 to 2021: a Korean serial cross-sectional study of one million adolescents
Park S, Yon H, Ban C, Shin H, Eum S, Lee S, Shin Y, Shin J, Koyanagi A, Jacob L, Smith L, Min C, Yeniova A, Kim S, Lee J, Hadalin V, Kwon R, Koo M, Fond G, Boyer L, Kim S, Hahn J, Kim N, Lefkir E, Bondeville V, Rhee S, Shin J, Yon D, Woo H. National trends in alcohol and substance use among adolescents from 2005 to 2021: a Korean serial cross-sectional study of one million adolescents. World Journal Of Pediatrics 2023, 19: 1071-1081. PMID: 36977821, PMCID: PMC10049906, DOI: 10.1007/s12519-023-00715-9.Peer-Reviewed Original ResearchConceptsPrevalence of current alcohol useWeighted prevalenceSubstance usePrevalence of substance useCurrent alcohol usePrevalence of alcohol consumptionPeriod of alcoholismCross-sectional studyBackgroundAlthough previous studiesKorean adolescentsSmoking statusConsumption prevalenceCross-sectional surveyInclusion criteriaAlcohol consumptionTobacco useAdolescent alcoholOverall prevalenceAlcohol useMid-pandemic periodsCOVID-19 pandemicDisease controlCOVID-19Prepandemic periodKorea Disease ControlCost-Effectiveness and Long-Term Savings of the Bright Bodies Intervention for Childhood Obesity
Pryor S, Savoye M, Nowicka P, Price G, Sharifi M, Yaesoubi R. Cost-Effectiveness and Long-Term Savings of the Bright Bodies Intervention for Childhood Obesity. Value In Health 2023, 26: 1183-1191. PMID: 36967028, PMCID: PMC10518029, DOI: 10.1016/j.jval.2023.03.006.Peer-Reviewed Original ResearchConceptsBody mass indexClinical controlMedical Expenditure Panel Survey dataClinical weight managementHealth system perspectivePrevention growth chartsParticipants' body mass indexFamily-based interventionsMass indexChildhood obesityBMI trajectoriesWeight managementHealthcare costsPrimary analysisGrowth chartsObesityTrial dataDisease controlMedical expendituresBright bodiesHealthcare expendituresIncremental costIntervention costsBody interventionsChildren
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply